Because benzimidazole anthelmintics (such as fenbendazole, mebendazole, and albendazole) undergo extensive hepatic first-pass metabolism via cytochrome P450 enzymes (including CYP2C19, CYP2J2, and CYP3A4), prolonged exposure or escalated dosing can trigger transaminase elevations and drug-induced liver injury (DILI). The NIH LiverTox database classifies fenbendazole as a cause of clinically apparent liver injury in humans following self-administration.
The sources outline safety and hepatic monitoring guidelines across formal clinical trials and clinical management of self-directed protocols:
1. Essential Laboratory Diagnostic Panel
When assessing hepatic safety, a standard Comprehensive Metabolic Panel (CMP) combined with a Complete Blood Count (CBC) is recommended to track the following specific biomarkers:
ALT (Alanine Aminotransferase): The primary, sensitive indicator of acute hepatocellular injury.
AST (Aspartate Aminotransferase): A secondary marker of hepatocyte damage (also found in skeletal and cardiac tissue).
ALP (Alkaline Phosphatase) & GGT (Gamma-Glutamyl Transferase): Evaluate bile duct integrity and help identify cholestatic or biliary epithelial injury.
Total Bilirubin: Assesses hepatic clearance, conjugation, and excretion.
INR (International Normalized Ratio) & Serum Albumin: Monitor the liver’s synthetic capability and evaluate for emerging coagulopathy.
CBC with Differential: Screens for bone marrow suppression (e.g., leukopenia or neutropenia), a known potential toxicity of prolonged high-dose benzimidazoles.

